title: Spheramine Titan/Schering.
abstract: Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006.
authors.affiliation: Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK. d.grosset@clinmed.gla.ac.uk
authors.forename: Donald
authors.initials: D
authors.lastname: Grosset
authors.forename: Katherine
authors.initials: K
authors.lastname: Grosset
mesh_terms: D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000379:methods* / Q000639:trends; D017322:Clinical Trials, Phase II as Topic; D004298:Dopamine / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D004337:Drug Carriers; D006801:Humans; D010300:Parkinson Disease / Q000628:therapy; D010857:Pigment Epithelium of Eye / Q000737:chemistry / Q000378:metabolism*; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends
chemical_list: D004337:Drug Carriers; D004298:Dopamine